MetaVia Inc. (MTVA) Financial Analysis & Valuation | Quarter Chart
MetaVia Inc. (MTVA)
MTVAPrice: $1.56
Fair Value: 🔒
🔒score
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel pharmaceuticals to treat cardiometabolic diseases. It develops DA-1241, a novel G-Protein-Coupled Receptor 119 agonist with development optionality as a standalone and/or combination therapy that is ... more
MetaVia Inc., a clinical-stage biotechnology company focuses on developing and commercializing novel... more
Description
Shares
| Market Cap | $3.60M | Exchange | NASDAQ |
| Sector | Healthcare | Industry | Biotechnology |
| Country | US | CEO | Heon Kim Hyung |
| IPO Date | 2016-08-05 | CAGR | — |
| Employees | 9 | Website | www.metaviatx.com |
| Div. Yield | — | Payout Ratio | — |
| Buy Back Yield | — | Total Yield | — |
MTVA chart loading...
Fundamentals
Technicals
| Enterprise Value | $-26.03M | P/E Ratio | -0.15 |
| Forward P/E | — | PEG Ratio | — |
| P/S Ratio | — | P/B Ratio | 1467439507955809050205204620846825472 |
| P/CF Ratio | -1467439507955809050205204620846825472 | P/FCF Ratio | -1467439507955809050205204620846825472 |
| EPS | $-10.45 | EPS Growth 1Y | — |
| EPS Growth 3Y | — | EPS Growth 5Y | — |
| Revenue Growth 1Y | — | Gross Margin | — |
| Operating Margin | — | Profit Margin | — |
| ROE | -2.12% | ROA | -1% |
| ROCE | -2.08% | Current Ratio | 2.08 |
| Quick Ratio | 2.08 | Cash Ratio | 1.99 |
| Debt/Equity | 0.01 | Interest Coverage | — |
| Altman Z Score | -13.41 | Piotroski Score | — |